TAT-10: Progress in the [At211]-Astatination of Antibodies by Nuclephilic Approaches Using Aryliodonium Salts Precursors

Kanazawa, Japan (UroToday.com) In this study, we develop a method for At211 radio-labeling based on aryliodonium salts and compare with the more conventional approach using arylstannane chemistry. We find improved yields of 43 +/- 2 % for aryliodonium compared with 20 +/- 5% for arylstannane.

We attribute this improvement to two factors: the stannane chemistry approach requires an extra purification step, and the iodonium process uses the very stable At- while the stannane requires an At+ ion.

Presented By: Francois Guerand from Centre de Recherche en Cancerologie Nantes-Angers (CRCNA), Unite INSERM 892 – CNRS 6299, Nantes, France

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.